- Home
- CISO vs IGC Comparison
CISO vs IGC Comparison
Compare CISO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISO | IGC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 31.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CISO | IGC |
|---|---|---|
| Price | $0.50 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 591.6K | ★ 938.4K |
| Earning Date | 11-13-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,743,266.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.25 |
| 52 Week High | $3.84 | $0.50 |
Technical Indicators
Market Signals| Indicator | CISO | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 32.70 |
| Support Level | $0.43 | $0.29 |
| Resistance Level | $0.49 | $0.31 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 68.98 | 4.47 |
Price Performance
Historical ComparisonAbout CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.